The Global Health European and Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU) has released its Work Programme for 2024.
In 2024, the GH EDCTP3 JU will distribute €140 million through two calls, which are planned to be launched on 18 January 2024, with a stage 1 deadline of 4 April 2024:
The HORIZON-JU-GH-EDCTP3-2024-01-two-stage call covers six topics for Research and Innovation Actions (RIA):
- Developing novel, innovative HIV therapeutics for reducing the disease burden of HIV in sub-Saharan Africa
- Research on existing Malaria vaccines and development of new promising candidates
- Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa
- Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
- New tools, technologies and approaches for vector control in sub-Saharan Africa
- Innovative digital health solutions for sub-Saharan Africa
The HORIZON-JU-GH-EDCTP3-2024-02-two-stage call will include one topic for Coordination and Support Actions (CSA):
- Global Health EDCTP3 JU training fellowship with a return phase.
The full description of the topics will be available when the calls open.